IP Library Granted Patent US 8,642,328
Granted Patent B2
US 8,642,328 · App. 12/905,839 · Granted Feb 4, 2014

Derivation of embryonic stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,328
App. No.
12/905,839
Granted
Feb 4, 2014
Kind
B2
Abstract

This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

Claims (17)

1. A method of producing a mammalian embryonic stem (ES) cell, the method comprising:

(a) culturing at least one blastomere obtained from a mammalian embryo with ES cells or embryo carcinoma cells until a clump containing blastomere progeny cells forms;

(b) further culturing the blastomere progeny cells for a suitable amount of time to obtain ES cells derived from the at least one blastomere; and

(c) isolating ES cells derived from the at least one blastomere.

2. The method of claim 1 , wherein the at least one blastomere is obtained from the mammalian embryo prior to or during compaction of the morula.

3. The method of claim 1 , wherein the at least one blastomere is obtained by partially or completely removing the zona pellucida surrounding the mammalian embryo.

4. The method of claim 1 , wherein the at least one blastomere is cultured with ES cells in step (a).

5. The method of claim 1 , further comprising detecting the expression of an ES cell marker protein by the ES cells derived from the at least one blastomere.

6. The method of claim 1 , wherein the mammalian embryo is a mouse, rabbit, sheep, pig, cow, or non-human primate embryo.

7. The method of claim 1 , wherein the at least one blastomere undergoes cell division and one progeny cell is used for genetic testing and a different progeny cell is used to produce an ES cell.

8. The method of claim 1 , wherein the ES cells derived from the at least one blastomere are cultured with an autologous feeder cell, wherein the feeder cell is obtained by culturing an additional blastomere obtained from said mammalian embryo under conditions to differentiate the additional blastomere to produce the autologous feeder cell.

9. The method of claim 1 , wherein the culture volume in step (a) is between about 5 microliters and about 50 microliters.

10. The method of claim 1 , wherein said mammalian embryo is between the 6-8 cell stage.

11. The method of claim 1 , wherein one or two blastomeres are removed from said mammalian embryo.

12. The method of claim 1 , wherein said mammalian embryo remains viable.

13. The method of claim 1 , wherein recombinant Oct-4 is introduced into the at least one blastomere or endogenous Oct-4 is activated in the at least one blastomere during step (a).

14. The method of claim 1 , wherein recombinant Oct-4 is introduced into the blastomere progeny cells or endogenous Oct-4 is activated in the blastomere progeny cells during step (b).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2014
From: CAMOFI MASTER LDC; CAMHZN MASTER LDC
To: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
Reel/Frame 034421/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: LANZA, ROBERT; CHUNG, YOUNG
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034023/0193 →
SECURITY AGREEMENT Recorded Jan 25, 2013
From: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
To: CAMOFI MASTER LDC; CAMHZN MASTER LDC
Reel/Frame 029698/0001 →